Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fresenius : Kabi launches its first specialty IV drug in the U.S.

12/01/2020 | 10:21am EST

Icatibant injection, an FDA-approved and cost-effective alternative to treat acute attacks of hereditary angioedema in adults, expands the company's generic drug portfolio. Icatibant Injection is supplied as a prefilled, single-use syringe that is self-administered subcutaneously at the patient's home or doctor's office. In conjunction with launching its first specialty IV drug in the U.S., Fresenius Kabi is also launching KabiCare in the U.S., a comprehensive patient support program with case managers, co-pay assistance programs, injection training, and a patient assistance program.

Disclaimer

Fresenius SE & Co. KGaA published this content on 01 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2020 15:20:01 UTC


© Publicnow 2020
All news about FRESENIUS SE & CO. KGAA
01/22European ADRs Move Lower in Friday Trading
MT
01/19Cytosorbents' CytoSorb Blood Purification Technology Gets Nod from South Kore..
MT
01/19DGAP-DD : Fresenius SE & Co. KGaA english
DJ
01/18FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs maintains a Buy rating
MD
01/18FRESENIUS SE : Goldman Sachs maintains a Buy rating
MD
01/13FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from JP Morgan
MD
01/12FRESENIUS SE : Buy rating from JP Morgan
MD
01/11FRESENIUS SE : Jefferies remains a Sell rating
MD
01/11FMC FRESENIUS MEDICAL CARE AG & CO K : Downgraded from Neutral to Sell by Jeffer..
MD
01/07European ADRs Move Higher in Thursday Trading
MT
More news
Financials
Sales 2020 36 285 M 44 155 M 44 155 M
Net income 2020 1 792 M 2 180 M 2 180 M
Net Debt 2020 24 048 M 29 265 M 29 265 M
P/E ratio 2020 12,0x
Yield 2020 2,09%
Capitalization 21 284 M 25 909 M 25 901 M
EV / Sales 2020 1,25x
EV / Sales 2021 1,13x
Nbr of Employees 309 114
Free-Float 72,0%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 48,44 €
Last Close Price 38,18 €
Spread / Highest target 78,1%
Spread / Average Target 26,9%
Spread / Lowest Target -53,7%
EPS Revisions
Managers and Directors
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors